Please assess the completion status of the following clinical trial:

Trial Title: Study of the Fecal Microbiome in Patients With Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of Parkinson's Disease (PD) for less than or equal to 10 years based on the United Kingdom Brain Bank Criteria and the Modified Hoehn-Yahr (H\&Y) staging system of less than 3 in the OFF medicine state of at least 8-12 hours (subjects should have an asymmetric and unilateral symptoms onset).~* Mild microsomia to anosmia (The University of Pennsylvania Smell Identification Test (UPSIT) less than 33), which is supportive of idiopathic PD.~* Robust response to dopaminergic therapy (defined as greater than 33% reduction in symptoms (on the Unified Parkinson's Disease Rating Scale part III (UPDRS-III)) when measured in the ON medicine state compared to OFF state.~* Subject has a history of constipation.~* Sexually active male and female subjects of child-bearing potential agree to use an effective method of birth control during the study.~* Female subjects of child-bearing potential must have a negative urine Qualitative Human chorionic gonadotropin (hCG) pregnancy test at enrollment and on the Week 1, Day 1 of the Treatment prior to administration of study drug.~* Willing and able to sign an informed consent form and attend study assessments and follow ups.~* Subject has an attending physician who will provide non-transplant care for the subject.~* Subject is able to maintain a stable Parkinson's therapy medical regimen during participation in the study.~Exclusion Criteria:~* Unable to take multiple capsules orally.~* Montreal Cognitive Assessment (MoCA) Score less than or equal to 23.~* Atypical, vascular or drug-induced Parkinsonism.~* Clinical features of psychosis or refractory hallucinations.~* Unstable Parkinson's disease symptomatic therapy (defined as recent changes or additions to the PD regimen).~* Compromised immune system (e.g. primary immune disorders or clinical immunosuppression due to a medical condition or medication e.g. taking systemic steroids greater than 20 milligrams (mg) a day or prednisone-equivalent)~* Receipt of systemic non-topical antibiotic therapy currently or within 14 days of enrollment.~* Prior Deep Brain Stimulation, or surgical intervention for PD, intravenous glutathione therapy or stem cell therapy.~* History of medium or large vessel cerebrovascular accidents.~* History of use of an investigational drug within 90 days prior to the screening visit.~* Positive results for human immunodeficiency virus (HIV) or Hepatitis B / C.~* Current history for active states of Inflammatory bowel disease, Irritable bowel syndrome, microscopic colitis, celiac disease, short gut syndrome, colostomy, colectomy, gastrointestinal fistulae or strictures.~* History of significant uncontrolled systemic disease that in the opinion of the study investigator could interfere with study participation and/or objectives.~* Life expectancy of less than 1 year.~* In the opinion of investigator, subject for any reason, should be excluded from the study

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Active group treated with healthy fecal microbiota (Type: EXPERIMENTAL): None
- Placebo group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete